A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study

Part of paid clinical trials in Tampa, Florida.

Sponsor
Kymera Therapeutics, Inc.
Study ID
NCT07677059
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Asthma (Diagnosis)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • KT-621 — DRUG
    Oral drug

Study Details

This Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for asthma. The main goals of this study are to investigate the long-term safety and tolerability of KT-621, the long-term efficacy of KT-621 at treating asthma, and how KT-621 behaves in the body long-term.

Key Dates

Start date
Jul 31, 2026
Status verified
Jun 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
264 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: KT-621

Primary Outcome Measure

Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: From baseline through Week 52 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Kymera Investigative SiteTampaFlorida33607-

Find similar trials in Tampa, FL

By research site
Kymera Investigative Site· Tampa, FL

Related Studies